Molecular Mechanism of miR-140 in Colon Cancer
Molecular Mechanism of miR-140 in Colon Cancer
批准号:
8680026
负责人:
JINGFANG JU
金额:
$37.5万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-08-01 至 2017-05-31
关键词:
BindingCD44 geneCXCL12 geneCancer PatientCell Cycle RegulationCell ProliferationCellsChondrocytesColon CarcinomaDevelopmentDiagnostic Neoplasm StagingExtracellular MatrixFailureFluorouracilFunctional RNAGenesGoalsGrowthGrowth FactorHumanIGFBP5 geneImmunoprecipitationIn VitroIndividualInsulin-Like Growth Factor Binding Protein 5Interleukin-1Interleukin-4LeadMalignant NeoplasmsMessenger RNAMetastatic Neoplasm to the LiverMethotrexateMicroRNAsMissionMolecularMolecular TargetMusNational Cancer InstituteNeoplasm MetastasisOligonucleotidesPathway interactionsPatientsPharmaceutical PreparationsPopulationRNARegulationResistanceSystemic TherapySystemic diseaseTherapeuticTranscriptTranscriptional ActivationTranslationsTumor BiologyTumor Cell InvasionTumor stageWestern Blottingbasecancer cellcancer stem cellcell motilitycellular transductionchemokinechemotherapycytokinecytotoxicdigitalfollow-uphuman HDAC4 proteinimprovedin vivoknock-downmigrationmouse modelnext generation sequencingnovelnovel strategiesoxaliplatinresistance mechanismstemstem cell populationtumortumor growthtumor microenvironmenttumor xenograft
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The ultimate goal of this project is to elucidate the molecular and cellular regulatory mechanisms of miR-140 in colon cancer. Human colon cancer is highly heterogeneous, and systemic drug treatment is almost never able to cure individuals with late stage tumors. One major reason for the failure of chemotherapy is the resistant cancer stem cell population: current chemotherapeutics target rapidly dividing cancer cells, but cancer stem cells divide slowly, and thus are relatively resistant to cytotoxic systemic therapies. Our recent studies showed that several non-coding miRNAs are involved in the resistance mechanism in colon cancer stem cells. In particular, we demonstrated that the cell proliferation of differentiated colon cancer cells was significantly reduced by over- expressing miR-140. As a result, these cells became more resistant to 5-fluorouracil (5-FU) or methotrexate (MTX) treatment. We further revealed that the expression of miR-140 was elevated in a small population of CD133+HICD44+HI colon cancer stem-like cells. These cells are highly resistant to 5-FU treatment, and by blocking miR-140 activity using anti-miR140 oligonucleotides, we were able to increase chemosensitivity to 5-FU (1). We also discovered that one of the key targets of miR-140 is histone deacetylase 4 (HDAC4), implying that miR-140 could potentially modulate transcriptional activation of genes involved in cell cycle control through HDAC4. Given the potential of this new paradigm whereby miRNAs, acting post-transcriptionally, can impact pathways leading to cancer growth and altered chemosensitivity, to offer new options for treatment, it is essential to follow up and extend our findings: We therefore propose three specific aims: (1) To investigate the mechanisms of miR-140 in contributing to proliferation, differentiation and chemoresistance in CD133+HICD44+HI colon cancer stem cells in vitro and in vivo; (2) To investigate the impact of miR-140 on colon cancer metastasis; and (3) To define the molecular targets and interaction networks impacted by miR-140, taking advantage of a powerful new approach, TrIP-Seq, to identify miRNA regulation at the translational level, even in small stem cell populations. This proposed project will provide the molecular basis for developing miR-140-based therapeutic strategies to overcome chemoresistance in colon cancer stem cells and to improve patient survival.
期刊论文(19)
专著(0)
科研奖励(0)
会议论文
Development of novel miRNA based novel therapeutics for metastatic colorectal cancer
-
批准号:10256956
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2022
-
负责人:JINGFANG JU
-
依托单位:
Development of novel miRNA based novel therapeutics for metastatic colorectal cancer
-
批准号:10512749
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2022
-
负责人:JINGFANG JU
-
依托单位:
Roles of miR-129 in colorecal cancer
-
批准号:9105488
-
项目类别:
-
资助金额:$35.92万
-
财政年份:2016
-
负责人:JINGFANG JU
-
依托单位:
Roles of miR-129 in colorecal cancer
-
批准号:9916629
-
项目类别:
-
资助金额:$35.92万
-
财政年份:2016
-
负责人:JINGFANG JU
-
依托单位:
Molecular Mechanism of miR-140 in Colon Cancer
-
批准号:8309960
-
项目类别:
-
资助金额:$39.35万
-
财政年份:2011
-
负责人:JINGFANG JU
-
依托单位:
Identification of post-transcriptionally regulated targets by TrIP-Chip/Seq
-
批准号:8311637
-
项目类别:
-
资助金额:$23.23万
-
财政年份:2011
-
负责人:JINGFANG JU
-
依托单位:
Molecular Mechanism of miR-140 in Colon Cancer
-
批准号:8495750
-
项目类别:
-
资助金额:$36.67万
-
财政年份:2011
-
负责人:JINGFANG JU
-
依托单位:
Identification of post-transcriptionally regulated targets by TrIP-Chip/Seq
-
批准号:8035099
-
项目类别:
-
资助金额:$22.5万
-
财政年份:2011
-
负责人:JINGFANG JU
-
依托单位:
Identification of post-transcriptionally regulated targets by TrIP-Chip/Seq
-
批准号:8504769
-
项目类别:
-
资助金额:$21.68万
-
财政年份:2011
-
负责人:JINGFANG JU
-
依托单位:
Molecular Mechanism of miR-140 in Colon Cancer
-
批准号:8185001
-
项目类别:
-
资助金额:$41.2万
-
财政年份:2011
-
负责人:JINGFANG JU
-
依托单位:
Novel Method for Isolating Actively Translated mRNAs
-
批准号:7230151
-
项目类别:
-
资助金额:$12.8万
-
财政年份:2006
-
负责人:JINGFANG JU
-
依托单位:
Novel Method for Isolating Actively Translated mRNAs
-
批准号:7085763
-
项目类别:
-
资助金额:$13.14万
-
财政年份:2006
-
负责人:JINGFANG JU
-
依托单位:
REGULATION OF P53 EXPRESSION BY THYMIDYLATE SYNTHASE
-
批准号:2861909
-
项目类别:
-
资助金额:$1.99万
-
财政年份:1999
-
负责人:JINGFANG JU
-
依托单位: